Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.

Biogen drops controversial Alzheimer's drug, focuses on other treatments

Biogen said it is discontinuing its controversial drug Aduhelm, so it can focus resources on other Alzheimer’s treatments that drive long-term growth.This includes shifting its priorities to its blockbuster drug Leqembi, which was developed with Japan's Eisai and approved in 2023."As a pioneer in Alzheimer’s disease, Biogen is reprioritizing resources to build a leading franchise to address the multiple pathologies of the disease and patient nee…

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.

Biogen will stop selling its controversial Alzheimer's drug Aduhelm

(AP) — Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago.